Journals / Turkish journal of nephrology (Online) / 2021 / Cilt: 30 - Sayı: 4

99mTc MDP Bone Scan Findings in CKD-MBD: Could the “Superscan” Image be Useful in Excluding Adynamic Bone Disease?

Pages
308–315
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that superscan images may be a diagnostic tool for high turnover bone disease, and they may have a role as an excluding tool of a dynamic bone disease especially before the use of bisphosphonates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To explore the association of superscan image in technetium 99m-labeled methylene diphosphonate bone scans with chemical parameters of high turnover bone disease and bone mineral density measurement findings in chronic peritoneal dialysis patients.
📊
Key Findings & Data:Methods: Technetium 99m-labeled methylene diphosphonate bone scans of 15 chronic peritoneal dialysis patients with superscan images were matched by their age, gender, dialysis vintage, body mass index, and Kt/V values with 20 patients with no superscan image.
💡
Conclusion & Impact:We believe that superscan images may be a diagnostic tool for high turnover bone disease, and they may have a role as an excluding tool of a dynamic bone disease especially before the use of bisphosphonates.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: To explore the association of superscan image in technetium 99m-labeled methylene diphosphonate bone scans with chemical parameters of high turnover bone disease and bone mineral density measurement findings in chronic peritoneal dialysis patients. Methods: Technetium 99m-labeled methylene diphosphonate bone scans of 15 chronic peritoneal dialysis patients with superscan images were matched by their age, gender, dialysis vintage, body mass index, and Kt/V values with 20 patients with no superscan image. Serum iPTH, Ca, P, 25(OH)D3, 1-25(OH)2D3, total and bone alkaline phosphatases, dual-energy X-ray absorptiometry-based bone mineral density results were measured. Results: Serum iPTH levels were significantly higher in superscan patients (587.3 ± 515.9 pg/ml vs 214.8 ± 224.9 pg/ml, P = .001) and correlated with the existence of superscan image (P = .007, r = −0.450) in bone scans. Total alkaline phosphatase levels were also significantly higher in superscan patients (414.7 ± 400.6 vs 235.6 ± 117.6 U/L, P = .046). Ca, P, CaXP, 25(OH)D3, 1-25(OH)2D3, bone alkaline phosphatase levels, and bone mineral densities were not different between groups. Conclusion: Superscan image in technetium 99m-labeled methylene diphosphonate bone scans correlated well with serum iPTH and total alkaline phosphatase levels, and therefore, it may be suggestive for high turnover bone disease in chronic peritoneal dialysis patients. Lack of any difference between groups regarding their bone mineral densities suggests that the main difference between groups may be a metabolic one, rather than being structural. We believe that superscan images may be a diagnostic tool for high turnover bone disease, and they may have a role as an excluding tool of a dynamic bone disease especially before the use of bisphosphonates.

🔖

Cite This Article

SARI, F., KARAYALÇIN, B., SÜLEYMANLAR, G., AKÇİÇEK, S. F., ATAMAN, R., AKPOLAT, T., BOZFAKİOĞLU, S., GÜLTEKIN, M., ERSOY, F. F. (2021). 99mTc MDP Bone Scan Findings in CKD-MBD: Could the “Superscan” Image be Useful in Excluding Adynamic Bone Disease?. Turkish journal of nephrology (Online), Cilt: 30 - Sayı: 4, 308–315. https://ajindex.com/articles/374939

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Covic A, Voroneanu L, Apetrii M. PTH and/or Bone Histology: Are we still waiting for a verdict from the ckd-mbd grand jury? Am J Kidney Dis. 2016;67(4):535-538. [CrossRef] 2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(suppl 113):S3-S8. 3. Suchowierska E, Myśliwiec M. Mineral and bone disturbances associated with chronic kidney disease. Pol Merkur Lekarski. 2010;28(164):138-143. 4. Iwasaki Y, Kazama JJ, Fukagawa M. Molecular abnormalities underlying bone fragility in chronic kidney disease. BioMed Res Int. 2017;2017:3485785. [CrossRef] 5. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-38. [CrossRef] 6. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205- 2215. [CrossRef] 7. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(1):396-399. [CrossRef] 8. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36(6):1115-1121. [CrossRef] 9. Šimunović I, Pavlović D, Kudumija B, et al. Bone fragility fractures in hemodialysis patients: Croatian surveys. Coll Antropol. 2015;39(1):71-74 10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. [CrossRef] 11. Nickolas TL, Stein E, Cohen A, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21(8):1371-1380. [CrossRef] 12. West SL, Lok CE, Langsetmo L, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. 2015;30(5):913-919. [CrossRef] 13. Bacchetta J, Boutroy S, Vilayphiou N, et al. Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease. J Bone Miner Res. 2010;25(4):849-85